Pfizer Chief Financial Officer Frank D’Amelio told an audience at a Goldman Sachs investment conference that the AstraZeneca deal fell apart over money, Bloomberg reports.

AstraZeneca turned down the $117 billion bid Memorial Day weekend, and Pfizer cannot approach the company until three months have lapsed.

Bloomberg reported earlier that perceived personal affronts also doomed Pfizer’s overture.